2. Search Result
Search Result
Results for "

bone resorption inhibitor

" in MedChemExpress (MCE) Product Catalog:

108

Inhibitors & Agonists

2

Screening-Bibliotheken

2

Biochemical Assay Reagents

13

Peptides

3

Inhibitory Antibodies

23

Natural
Products

5

Isotope-Labeled Compounds

Art. -Nr. Produktname Target Forschungsgebiete Chemical Structure
  • HY-P0090
    Calcitonin (salmon)
    2 Publications Verification

    Salmon calcitonin

    		 CGRP Receptor Cancer
    Calcitonin salmon, a calcium regulating hormone, is a dual-action amylin and calcitonin receptor agonist, could stimulate bone formation and inhibit bone resorption.
    Calcitonin (salmon)
  • HY-112499
    Menaquinone-7
    3 Publications Verification

    Vitamin K2-7; Vitamin K2(35); Vitamin MK-7

    		 TGF-beta/Smad Cardiovascular Disease
    Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7
  • HY-P2273
    Calcitonin (human)

    		CGRP Receptor Metabolic Disease
    Calcitonin (human) is a hypocalcemic hormone. Calcitonin can lower blood calcium levels and inhibit bone resorption. Calcitonin can be used in hypercalcemia or osteoporosis research .
    Calcitonin (human)
  • HY-B0631
    Alendronic acid
    Maximum Cited Publications
    10 Publications Verification

    		 NF-κB Interleukin Related Metabolic Disease
    Alendronate acid is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate acid induces skeletal alterations in the chicken embryonic development model. Alendronate acid can be used for osteoporosis research .
    Alendronic acid
  • HY-108685
    Alendronate sodium
    Maximum Cited Publications
    10 Publications Verification

    Alendronic acid monosodium salt

    		 NF-κB Interleukin Related Metabolic Disease
    Alendronate sodium is an orally active bisphosphonate which binds to bone surfaces and inhibits bone resorption by osteoclasts. Alendronate sodium induces skeletal alterations in the chicken embryonic development model. Alendronate sodium can be used for osteoporosis research .
    Alendronate sodium
  • HY-B0657A
    Clodronic acid disodium salt
    4 Publications Verification

    Clodronate disodium salt

    		 Apoptosis Metabolic Disease Cancer
    Clodronic acid (Clodronate) disodium salt is an orally active bisphosphonate. Clodronic acid disodium salt inhibits osteoclast-mediated bone resorption. Clodronic acid disodium salt reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid disodium salt is effective in the maintenance or improvement of bone mineral density. Clodronic acid disodium salt can be used for the research of multiple myeloma and postmenopausal osteoporosis .
    Clodronic acid disodium salt
  • HY-B0302
    Etidronic acid
    1 Publications Verification

    Etidronate; HEDPA; HEDP

    		 Environmental Pollutants Apoptosis Metabolic Disease Cancer
    Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid
  • HY-N0721
    Neoandrographolide
    1 Publications Verification

    Neoandrographiside

    		 ERK p38 MAPK JNK NF-κB PI3K PPAR GSK-3 CaMK NO Synthase Reactive Oxygen Species (ROS) Apoptosis Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    Neoandrographolide is a diterpenoid compound isolated from Andrographis paniculata. Neoandrographolide inhibits osteoclasts differentiation and bone resorption through inhibition of MAPK/NF-κB/PI3K/AKT/GSK3β/PPAR/CAMK signaling pathway. Neoandrographolide inhibits apoptosis in rat embryonic ventricular cardiomyocytes. Neoandrographolide inhibits iNOS and the generation of ROS, activates eNOS, exhibiting anti-inflammatory and hypolipidemic activity .
    Neoandrographolide
  • HY-B0148
    Risedronic acid
    2 Publications Verification

    Risedronate

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
    Risedronic acid
  • HY-A0020
    Eldecalcitol
    4 Publications Verification

    ED-71; 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3

    		 VD/VDR Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Eldecalcitol (ED-71) is an orally active vitamin D3 analogue, inhibits bone resorption and increases bone mineral density. Eldecalcitol (ED-71) displays anti-tumor effect and inhibits cell proliferation, migration and induces apoptosis by suppressing GPx-1 .
    Eldecalcitol
  • HY-B0302A
    Etidronic acid disodium
    1 Publications Verification

    Etidronate disodium; HEDPA disodium; HEDP disodium

    		 Apoptosis Metabolic Disease Cancer
    Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid disodium
  • HY-P99590A
    Sotatercept (mIgG2a)
    1 Publications Verification

    RAP-011

    		 TGF-β Receptor TGF-beta/Smad Cardiovascular Disease Metabolic Disease
    Sotatercept (mIgG2a) (RAP-011), the murine homolog of Sotatercept (ACE-011) (HY-P99590), is a soluble activin receptor type IIA (ActRIIA) ligand trap. Sotatercept (mIgG2a) inhibits the binding of activin A and other members of the TGF-β superfamily (such as Activin A/B, GDF11 and BMP9/10) to their receptors by combining and neutralizing them, thereby regulating cell proliferation and differentiation. Sotatercept (mIgG2a) mainly inhibits the SMAD2/3 signaling pathway, and can be used in various diseases such as chronic kidney disease. Sotatercept (mIgG2a) reduces the expression of erythropoietic hepcidin (ERFE), regulates iron metabolism, and promotes red blood cell production. Sotatercept (mIgG2a) has a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (catabolic) .
    Sotatercept (mIgG2a)
  • HY-N2532
    Diphyllin
    3 Publications Verification

    		 VSV HIV Proton Pump Influenza Virus Infection Inflammation/Immunology Cancer
    Diphyllin is an orally active V-ATPase inhibitor (IC50=17 nM) and HIV-1 inhibitor (IC50=0.38 μM). Diphyllin blocks the acidification of osteoclast lysosomes and bone resorption lacunas (IC50=0.6 nM for acid influx inhibition)， thereby inhibiting bone resorption. Diphyllin can effectively inhibit osteoclast-mediated bone resorption and has no effect on osteoblastic bone formation. Diphyllin can be used in the research of bone metabolism-related diseases and has the potential to inhibit diseases related to excessive bone resorption .
    Diphyllin
  • HY-B1246
    Thonzonium bromide
    5+ Cited Publications

    		 Bacterial Proton Pump Infection
    Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
    Thonzonium bromide
  • HY-N0257
    Epimedin A
    4 Publications Verification

    		 PI3K Akt NF-κB NOD-like Receptor (NLR) Keap1-Nrf2 Heme Oxygenase (HO) SOD Caspase Interleukin Related Metabolic Disease Inflammation/Immunology
    Epimedin A, one of the main flavonoid active components in Herba Epimedii, is orally active. Epimedin A can inhibit osteoclastogenesis, differentiation, and bone resorption. Epimedin A also possesses anti-inflammatory activity. Epimedin A can be used in the research of osteoporosis and inflammatory diseases .
    Epimedin A
  • HY-B0119
    Risedronic acid sodium
    2 Publications Verification

    Risedronate sodium

    		 Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Risedronate) sodium, a bisphosphonate, is a potent anti-resorption agent that inhibits osteoclast-mediated bone resorption and changes the bone metabolism. Risedronic acid sodium suppresses osteoblast differentiation and induced caspase- and isoprenoid depletion-dependent apoptosis. Risedronic acid sodium inhibits blood stages of Plasmodium falciparum (IC50 of 20.3 μM). Risedronic acid sodium inhibits the transfer of the farnesyl pyrophosphate group to parasite proteins .
    Risedronic acid sodium
  • HY-110318
    VUF11207 fumarate
    3 Publications Verification

    		 CXCR Inflammation/Immunology Cancer
    VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
    VUF11207 fumarate
  • HY-12398
    TEI-9647
    2 Publications Verification

    		 VD/VDR Metabolic Disease Inflammation/Immunology
    TEI-9647, a Vitamin D3 Lactone analogue, is a potent and specific vitamin D receptor (VDR) antagonist. TEI-9647 inhibits VDR/VDRE-mediated genomic actions of 1α,25(OH)2D3. TEI-9647 inhibits bone resorption and HL-60 cell differentiation induced by of 1α,25(OH)2D3. TEI-9647 has the potential for suppressing the excessive bone resorption and osteoclast formation in Paget's disease .
    TEI-9647
  • HY-N6084
    Humulone

    α-Lupulic acid

    		 COX GABA Receptor Apoptosis Cardiovascular Disease
    Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent cyclooxygenase-2 (COX-2) inhibitor. Humulone acts as a positive modulator of GABAA receptor at low micromolar concentrations. Humulone is an inhibitor of bone resorption. Humulone possesses antioxidant, anti-angiogenic and apoptosis-inducing properties .
    Humulone
  • HY-B0515
    Ibandronate Sodium Monohydrate
    1 Publications Verification

    BM-210955; RPR-102289A

    		 Apoptosis Metabolic Disease Cancer
    Ibandronate Sodium Monohydrate (BM-210955; RPR-102289A) is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium Monohydrate can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium Monohydrate inhibits tumor cell proliferation (such as ER + breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium Monohydrate is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
    Ibandronate Sodium Monohydrate
  • HY-N4288
    4-Methylesculetin
    3 Publications Verification

    		 Glutathione Peroxidase Cathepsin Phosphatase Inflammation/Immunology Cancer
    4-Methylesculetin is an orally active coumarin derivative, with potent anti-oxidant and anti-inflammatory activities. 4-Methylesculetin inhibits myeloperoxidase activity. 4-Methylesculetin protects bone resorption by reducing the elevated levels of bone-joint exoglycosidases, cathepsin-D and tartrate resistant acid phosphatases. 4-Methylesculetin ameliorats the upregulated non-enzymatic inflammatory markers like TNF-α, IL-1β, IL-6, COX-2 and PGE2, which is promising for research of inflammatory diseases .
    4-Methylesculetin
  • HY-114275
    Justicidin B

    		Fungal Parasite Apoptosis Infection Cardiovascular Disease Cancer
    Justicidin B is a potent anticancer lignan and proapoptotic agent. Justicidin B is also a bone resorption inhibitor, and has strong antiviral, fungicidal, antiprotozoal effects. Justicidin B significantly inhibits platelet aggregation .
    Justicidin B
  • HY-P0322
    GRGDSPK

    EMD 56574

    		 Integrin Cardiovascular Disease Metabolic Disease
    GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption .
    GRGDSPK
  • HY-103352
    L-006235

    L-235

    		 Cathepsin Metabolic Disease
    L-006235 (L-235) is a potent, selective, reversible and orally active inhibitor of cathepsin K, with an IC50 of 5 nM in bone resorption assay. L-006235 shows selectivity for cathepsin K (Ki=0.2 nM) over cathepsin B, cathepsin L, and cathepsin S (Ki=1, 6, and 47 μM, respectively). L-006235 can reduce collagen degradation and prevent bone loss .
    L-006235
  • HY-B2162B
    Chondroitin sulfate sodium (from bovine)

    Chondroitin polysulfate sodium (from bovine)

    		 Reactive Oxygen Species (ROS) Endogenous Metabolite Inflammation/Immunology
    Chondroitin sulfate (Chondroitin polysulfate) sodium (from bovine)) is a sulfated linear polysaccharide extracted from bovine sources, belonging to glycosaminoglycans. Chondroitin sulfate sodium (from bovine) inhibits osteoclast-mediated bone resorption and exhibits antioxidant activity, which is negatively correlated with molecular weight. Chondroitin sulfate sodium (from bovine) can be used in studies related to osteoarthritis .
    Chondroitin sulfate sodium (from bovine)
  • HY-108059
    β-Cryptoxanthin

    (3R)-β-Cryptoxanthin

    		 Drug Derivative Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    β-Cryptoxanthin ((3R)-β-Cryptoxanthin) is an orally active carotenoid found in fruits and vegetables such as angerines, red peppers, and pumpkin. β-Cryptoxanthin inhibits prevents osteoclast formation and inhibits bone resorption. β-Cryptoxanthin maintains retinol status in vivo. β-cryptoxanthin shows anti-inflammation and anticancer activity. β-Cryptoxanthin can be used for the researches of osteoporosis and bladder carcer .
    β-Cryptoxanthin
  • HY-10294
    Relacatib

    SB-462795

    		 Cathepsin Metabolic Disease Cancer
    Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo .
    Relacatib
  • HY-B0657
    Clodronic acid
    4 Publications Verification

    Clodronate

    		 Apoptosis Metabolic Disease Cancer
    Clodronic acid (Clodronate) is an orally active bisphosphonate. Clodronic acid inhibits osteoclast-mediated bone resorption. Clodronic acid reduces skeletal event risk in malignant bone disease, impairs malignant osteolysis, blocks bone matrix growth-factor release, induces apoptosis in osteoclasts and macrophages. Clodronic acid is effective in the maintenance or improvement of bone mineral density. Clodronic acid can be used for the research of multiple myeloma and postmenopausal osteoporosis .
    Clodronic acid
  • HY-P1189
    Echistatin

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin
  • HY-N9331
    Cimicifugoside H-1

    Cimicidanol-3-O-β-d-xyloside

    		 Others Metabolic Disease
    Cimicifugoside H-1, a cyclolanostanol xyloside, is a major constituent of C. foetida L. extract. Cimicifugoside H-1 inhibits bone resorption and ovariectomy-induced bone loss .
    Cimicifugoside H-1
  • HY-B0515B
    Ibandronate Sodium
    1 Publications Verification

    		 Apoptosis Metabolic Disease Cancer
    Ibandronate Sodium is an orally active, selective inhibitor of farnesyl pyrophosphate synthase (FPP synthase). Ibandronate Sodium can block the mevalonate pathway to inhibit the isoprenylation modification of small GTPases (such as RAS, RHO family proteins), induce tumor cell apoptosis and inhibit bone resorption. Ibandronate Sodium inhibits tumor cell proliferation (such as ER+ breast cancer cells), promotes the expression of the pro-apoptotic gene FAS, and can produce synergistic anti-tumor effects with anti-estrogen compounds. Ibandronate Sodium is used in the study of osteoporosis and bone metastatic tumors (such as breast cancer bone metastasis) .
    Ibandronate Sodium
  • HY-P1189A
    Echistatin TFA

    		Integrin Metabolic Disease Inflammation/Immunology
    Echistatin TFA, the smallest active RGD protein belonging to the family of disintegrins that are derived from snake venoms, is a potent inhibitor of platelet aggregation. Echistatin is a potent inhibitor of bone resorption in culture. Echistatin is a potent antagonist of αIIbβ3, αvβ3 and α5β1 .
    Echistatin TFA
  • HY-N1746
    (2S)-2'-Methoxykurarinone

    2'-O-Methylkurarinone

    		 RANKL/RANK Metabolic Disease Inflammation/Immunology Cancer
    (2S)-2'-Methoxykurarinone, a compound isolated from the roots of Sophora flavescens, has anti-inflammatory, antipyretic, antidiabetic, and antineoplastic effects. (2S)-2'-Methoxykurarinone (MK) inhibits osteoclastogenesis and bone resorption through down-regulation of RANKL signaling. (2S)-2'-Methoxykurarinone (MK) displays cytotoxic activity against human myeloid leukemia HL-60 cells .
    (2S)-2'-Methoxykurarinone
  • HY-N14323
    Madindoline A

    		Interleukin Related STAT Metabolic Disease
    Madindoline A is an orally active gp130 antagonist with a KD of 288 μM. Madindoline A inhibits IL-6- and IL-11-induced osteoclastogenesis, suppresses IL-6-stimulated serum amyloid A protein production, inhibits bone resorption and bone loss, and also inhibits IL-6- and IL-11-dependent cell line growth, as well as IL-6-dependent Stat3 tyrosine phosphorylation. Madindoline A is applicable for the research of hormone-dependent postmenopausal osteoporosis .
    Madindoline A
  • HY-16322
    Minodronic acid
    1 Publications Verification

    YM-529

    		 P2X Receptor Apoptosis Farnesyl Transferase Metabolic Disease Cancer
    Minodronic acid (YM-529) is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid induces tumor cell apoptosis and inhibits cell growth. Minodronic acid also suppresses bone resorption. Minodronic acid can be used in research related to osteoporosis and cancer .
    Minodronic acid
  • HY-16322A
    Minodronic acid hydrate
    1 Publications Verification

    YM-529 hydrate

    		 P2X Receptor Apoptosis Metabolic Disease Cancer
    Minodronic acid (YM-529) hydrate is an FPP synthase inhibitor with an IC50 of 3 nM, and also an antagonist of P2X2/3 receptors with an IC50 of 62.7 μM. Minodronic acid hydrate induces tumor cell apoptosis and inhibits cell growth. Minodronic acid hydrate also suppresses bone resorption. Minodronic acid hydrate can be used in research related to osteoporosis and cancer .
    Minodronic acid hydrate
  • HY-102065
    SC-19220

    		Prostaglandin Receptor RANKL/RANK Metabolic Disease
    SC-19220 is a prostaglandin E2 receptor EP1 antagonist. SC-19220 blocks functional EP1 receptor activation, and RANK/RANKL signaling pathway. SC-19220 inhibits osteoclast formation and bone resorption by pre-existing osteoclasts. SC-19220 can be used for the research of osteoporotic disorders, inflammatory bone resorption .
    SC-19220
  • HY-123370
    FR-167356

    		Proton Pump Metabolic Disease Cancer
    FR-167356 is a potent, orally active and selective vacuolar ATPase inhibitor with IC50 values of 170, 220, 370, and 1200 nM for osteoclast plasma membranes, macrophage microsomes, renal brush border membranes, and liver lysosomal membranes, respectively. FR-167356 inhibits bone resorption and ovariectomy-induced bone loss .
    FR-167356
  • HY-149149
    Incadronic acid

    		Bacterial Infection Metabolic Disease Cancer
    Incadronic acid inhibits growth of Dictyostelium discoideum with an IC50 of 1.6 μM. Incadronic acid binds the farnesyl diphosphate synthase (FPPS) in Leishmania major with the Ki of 23 nM. Incadronic acid inhibits the bone resorption and reduces bone loss, that can be used in osteoporosis research. Incadronic acid inhibits the proliferation of cells RAW264.7, PC-3 and MCF-7 with IC50 of 48 to 228.6 µM .
    Incadronic acid
  • HY-112499R
    Menaquinone-7 (Standard)
    3 Publications Verification

    Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)

    		 Endogenous Metabolite Reference Standards Cardiovascular Disease
    Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7 (Standard)
  • HY-B2097
    Incadronate disodium

    YM 175; Bisphonal

    		 Farnesyl Transferase Metabolic Disease
    Incadronate disodium (YM 175) is a bisphosphonate with strong inhibitory activity on bone resorption. Incadronate disodium indirectly stimulates renal 25-hydroxyvitamin D-1-hydroxylase by increasing circulating parathyroid hormone. Incadronate disodium, a cholesterol-lowering agent, is a potent inhibitor of rat liver microsomal squalene synthase (Ki=57 nM). Incadronate disodium inhibits sterol biosynthesis in mouse macrophage J774 cells (IC50=64 μM). Incadronate disodium has the potential for malignant tumors research .
    Incadronate disodium
  • HY-N5023
    Veraguensin

    		Others Metabolic Disease
    Veraguensin is a lignan compound derived from Magnolia sp.. Veraguensin can inhibit bone resorption
    Veraguensin
  • HY-P1288
    Protein Kinase C (530-558)

    PKC fragment (530-558)

    		 PKC Others
    Protein Kinase C (530-558), a peptide fragment of protein kinase C (PKC), is a potent PKC activator. Protein Kinase C (530-558) significantly inhibits osteoclastic bone resorption .
    Protein Kinase C (530-558)
  • HY-P4798
    Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat)

    Human PTHrP(107-111) amide

    		 PTHR Others
    Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat) (Human PTHrP (107-111) amide) is a C-terminal parathyroid hormone-related protein fragment that can inhibit bone resorption .
    Osteostatin (1-5) amide (human, bovine, dog, horse, mouse, rabbit, rat)
  • HY-B0631S
    Alendronic acid-d6

    		Isotope-Labeled Compounds Cancer
    Alendronic acid-d6 is the deuterium labeled Alendronic acid. Alendronic acid, a bisphosphonate, is a farnesyl diphosphate synthase (FDPS) inhibitor. Alendronic acid inhibits osteoclast-mediated bone resorption. Alendronic acid shows efficacy in postmenopausal osteoporosis, malignant hypercalcemia and Paget’s disease .
    Alendronic acid-d6
  • HY-129337
    Reveromycin A

    		Antibiotic Fungal Apoptosis Infection Cancer
    Reveromycin A, a benzoquinoid antibiotic isolated from the genus Streptomyces, is a selective inhibitor of protein synthesis in eukaryotic cells. Reveromycin A inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Reveromycin A has antiproliferative activity against tumor cell lines and antifungal activity .
    Reveromycin A
  • HY-B0148R
    Risedronic acid (Standard)

    Risedronate (Standard)

    		 Parasite Reference Standards Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid (Standard) (Risedronate (Standard)) is the analytical standard of Risedronic acid (HY-B0148). This product is intended for research and analytical applications. Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM).
    Risedronic acid (Standard)
  • HY-B0148S
    Risedronic acid-d4

    Risedronate-d4

    		 Isotope-Labeled Compounds Parasite Apoptosis Infection Metabolic Disease Cancer
    Risedronic acid-d4 (Risedronate-d4) is the deuterium labeled Risedronic acid (HY-B0148). Risedronic acid (Risedronate) is a bisphosphonate and potent antiresorptive agent. Risedronic acid induces Apoptosis. Risedronic acid inhibits the transfer of farnesyl pyrophosphate groups to parasite proteins. Risedronic acid inhibits osteoclast-mediated bone resorption and alters bone metabolism. Risedronic acid inhibits blood-stage Plasmodium falciparum (IC50 of 20.3 μM) .
    Risedronic acid-d4
  • HY-50887
    L-873724

    		Cathepsin Metabolic Disease
    L-873724 is a potent, orally bioavailable, selective and reversible non-basic cathepsin K inhibitor, with IC50s of 0.2, 178, 264, and 5239 nM for cathepsin K, cathepsin S, cathepsin L, cathepsin B, respectively . L-873724 also exhibits an IC50 of 0.5 nM for rabbit cathepsin K. L-873724 inhibits bone resorption .
    L-873724
  • HY-W107722
    IN04

    		LRRK2 Endocrinology
    IN04 is a inhibitor of leucine-rich repeat kinase 1 (LRRK1). IN04 can completely block the binding of ATP to the human LRRK1 kinase domain, thereby inhibiting the kinase activity of LRRK1. IN04 can significantly impair the bone resorption ability of osteoclasts, with an IC50 value of 5.72 μM. IN04 can be used for the study of osteoporosis .
    IN04

Online-Anfrage

Your information is safe with us. * Required Fields.

Anrede

  

Country or Region *

Name des Antragstellers *

 

Name der Organisation *

Department *

     

E-Mail-Addresse *

 

Produktname *

Art. -Nr.

  

Requested quantity *

Telefonnummer *

     

Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent: